Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC decreased its stake in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) by 1.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 67,350 shares of the company’s stock after selling 1,000 shares during the period. Nisa Investment Advisors LLC owned 0.06% of Apellis Pharmaceuticals worth $4,032,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. First Horizon Advisors Inc. increased its position in shares of Apellis Pharmaceuticals by 69.0% in the third quarter. First Horizon Advisors Inc. now owns 649 shares of the company’s stock worth $25,000 after acquiring an additional 265 shares in the last quarter. Covestor Ltd increased its position in shares of Apellis Pharmaceuticals by 564.2% in the third quarter. Covestor Ltd now owns 797 shares of the company’s stock worth $30,000 after acquiring an additional 677 shares in the last quarter. Stephens Consulting LLC acquired a new stake in shares of Apellis Pharmaceuticals in the third quarter worth $38,000. US Bancorp DE increased its position in shares of Apellis Pharmaceuticals by 391.2% in the first quarter. US Bancorp DE now owns 1,110 shares of the company’s stock worth $56,000 after acquiring an additional 884 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Apellis Pharmaceuticals by 29.3% in the third quarter. China Universal Asset Management Co. Ltd. now owns 3,028 shares of the company’s stock worth $115,000 after acquiring an additional 687 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Insiders Place Their Bets

In related news, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the completion of the sale, the insider now directly owns 1,115,983 shares in the company, valued at $60,452,799.11. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, insider Pascal Deschatelets sold 69,107 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The shares were sold at an average price of $54.17, for a total transaction of $3,743,526.19. Following the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at $60,452,799.11. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Jeffrey Eisele sold 438 shares of the firm’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $66.81, for a total transaction of $29,262.78. Following the transaction, the insider now directly owns 72,650 shares in the company, valued at approximately $4,853,746.50. The disclosure for this sale can be found here. Insiders sold a total of 422,279 shares of company stock worth $26,174,364 over the last ninety days. 7.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on APLS. UBS Group increased their price objective on shares of Apellis Pharmaceuticals from $87.00 to $89.00 and gave the stock a “buy” rating in a research report on Monday, March 4th. Oppenheimer upped their target price on shares of Apellis Pharmaceuticals from $75.00 to $79.00 and gave the company an “outperform” rating in a research note on Tuesday, January 30th. HC Wainwright restated a “buy” rating and issued a $92.00 target price on shares of Apellis Pharmaceuticals in a research note on Wednesday, February 28th. Raymond James upped their target price on shares of Apellis Pharmaceuticals from $67.00 to $106.00 and gave the company a “strong-buy” rating in a research note on Thursday, January 11th. Finally, Mizuho restated a “neutral” rating and issued a $60.00 target price on shares of Apellis Pharmaceuticals in a research note on Wednesday, March 27th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $78.60.

Apellis Pharmaceuticals Stock Down 2.0 %

Apellis Pharmaceuticals stock opened at $55.73 on Friday. The stock has a market cap of $6.72 billion, a price-to-earnings ratio of -12.44 and a beta of 0.88. The company has a current ratio of 3.10, a quick ratio of 2.50 and a debt-to-equity ratio of 0.48. The company’s 50-day moving average price is $61.77 and its two-hundred day moving average price is $56.64. Apellis Pharmaceuticals, Inc. has a 52 week low of $19.83 and a 52 week high of $94.75.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Tuesday, February 27th. The company reported ($0.73) earnings per share for the quarter, meeting the consensus estimate of ($0.73). Apellis Pharmaceuticals had a negative net margin of 133.34% and a negative return on equity of 178.60%. The company had revenue of $146.38 million during the quarter, compared to analyst estimates of $143.34 million. During the same quarter last year, the firm posted ($1.50) EPS. The business’s revenue for the quarter was up 545.9% on a year-over-year basis. On average, analysts expect that Apellis Pharmaceuticals, Inc. will post -1.36 EPS for the current fiscal year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).